Back to News
Market Impact: 0.42
Abbisko's Lavengratinib Shows Early Growth Benefit In Children With Achondroplasia
Source: Nasdaq
Healthcare & BiotechProduct LaunchesCompany Fundamentals
Abbisko Therapeutics reported positive preliminary Phase II data for avengratinib (ABSK061) in achondroplasia, the most common form of dwarfism. The encouraging early clinical results could support further development of the treatment and represent a positive catalyst for the company’s biotech pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
More News
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- RIP the Cybertruck: Elon Musk says Tesla will wind down production of its most polarizing EV
- Tesla will stop making the Cybertruck in 2027
- Tesla is 'winding down' Cybertruck production at its Texas Gigafactory
- Small retailers brace for 'huge hit' this holiday season as shipping costs spike
- AI won’t pay off for the S&P 493 until CEOs rebuild the work